Grid picks Catalent to make mAb for solid tumours

By Flora Southey contact

- Last updated on GMT


Related tags: Cancer, Immune system, Lung cancer

Grid Therapeutics has selected Catalent Pharma Solutions to develop and manufacture its antibody candidate to treat solid tumours.

Under the agreement, Catalent will use its GPEx technology to develop the cell line for Grid, and perform development activities through to drug manufacturing.

Catalent’s Rob Gustines told us Grid will be responsible for the commercialisation of the mAb.

“Catalent’s role is to support the development of the antibody for Grid Therapeutics, who will determine the future of the programme’s commercialisation,” ​Gustines told us.

The project – sponsored by Grid – will be undertaken at Catalent’s Madison, Wisconsin-based manufacturing site.

IgG mAb

Grid identifies its tumour immunoglobulin G (IgG) antibodies from patients with early stage cancer.

“The antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis,” ​said Grid.

Grid’s lead candidate is the first human derived targeted immunotherapy for cancer.

Last month, Catalent announced​ it would buy Cook Pharmica to expand its biologics, cell culture manufacturing and packaging capabilities.

Related news

Show more

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 05-Aug-2020 | Technical / White Paper

Traditional methods for adventitious agent testing rely on biological amplification and detection, which can take several weeks. This time-consuming approach...

Related suppliers

Follow us


View more